VENUSREM

Venus Remedies Share Price

 

 

Start SIP in VENUSREM

Start SIP

Performance

  • Low
  • ₹726
  • High
  • ₹752
  • 52 Week Low
  • ₹278
  • 52 Week High
  • ₹840
  • Open Price₹752
  • Previous Close₹759
  • Volume27,949
  • 50 DMA₹729.08
  • 100 DMA₹659.49
  • 200 DMA₹566.75

Investment Returns

  • Over 1 Month -1.32%
  • Over 3 Month + 64.56%
  • Over 6 Month + 49.86%
  • Over 1 Year + 103.7%

Smart Investing Starts Here Start SIP with Venus Remedies for Steady Growth!

Invest Now

Venus Remedies Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.9
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 982
  • P/B Ratio
  • 1.7
  • Average True Range
  • 43.73
  • EPS
  • 57.09
  • Dividend Yield
  • 0
  • MACD Signal
  • 9.17
  • RSI
  • 45.31
  • MFI
  • 52.12

Venus Remedies Financials

Venus Remedies Technicals

EMA & SMA

Current Price
₹734.45
-24.1 (-3.18%)
pointer
  • Bearish Moving Average 10
  • Bullish Moving Average 6
  • 20 Day
  • ₹761.82
  • 50 Day
  • ₹729.08
  • 100 Day
  • ₹659.49
  • 200 Day
  • ₹566.75

Resistance and Support

737.53 Pivot Speed
  • R3 775.22
  • R2 763.68
  • R1 749.07
  • S1 722.92
  • S2 711.38
  • S3 696.77

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Venus Remedies has an operating revenue of Rs. 699.88 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 11% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 43% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 70 which is a FAIR score but needs to improve its earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venus Remedies Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-29 Quarterly Results & Others To consider other business matters.
2025-11-10 Quarterly Results
2025-08-01 Quarterly Results
2025-07-08 Others Inter-alia, to consider 1. Notice of 36th Annual General Meeting. 2. Boards Report for Financial Year 2024-2025. 3. Other business matters.
2025-05-26 Audited Results

Venus Remedies F&O

Venus Remedies Shareholding Pattern

41.76%
2.25%
45.16%
10.83%

About Venus Remedies

  • NSE Symbol
  • VENUSREM
  • BSE Symbol
  • 526953
  • Chairman & Managing Director
  • Mr. Pawan Chaudhary
  • ISIN
  • INE411B01019

Similar Stocks to Venus Remedies

Venus Remedies FAQs

Venus Remedies share price is ₹734 As on 08 February, 2026 | 14:49

The Market Cap of Venus Remedies is ₹981.7 Cr As on 08 February, 2026 | 14:49

The P/E ratio of Venus Remedies is 12.9 As on 08 February, 2026 | 14:49

The PB ratio of Venus Remedies is 1.7 As on 08 February, 2026 | 14:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23